Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297555 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL4996629 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL19741239 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL6700235 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1668363 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1964137 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL11559107 | 0.97 | TDP1 (0.60) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL7789495 | 0.95 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL18264410 | 0.95 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL18877220 | 0.95 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425904-A | Supported Ziegler-Natta catalyst and preparation method and application thereof | 山东京博石油化工有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-9981998-B2 | Water-soluble acetaminophen analogs | ACORDA THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-9951001-B2 | Hepatoprotectant acetaminophen mutual prodrugs | ACORDA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. | 2016-11-10 | — | — | US | claimed |
| US-20160264605-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | NEUROGESX, INC. | 2016-09-15 | — | — | US | claimed |
| US-8735376-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | claimed |
| US-20110263545-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | ACORDA THERAPEUTICS, INC. | 2011-10-27 | — | — | US | claimed |
| US-20110212926-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | NEUROGESX, INC. (US) | 2011-09-01 | — | — | US | claimed |
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2011-09-01 | — | — | US | claimed |
| JP-2011520977-A | — | — | 2011-07-21 | — | — | JP | claimed |
| EP-2291348-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | Neurogesx, Inc. (US) | 2011-03-09 | — | — | EP | claimed |
| EP-2291084-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | Neurogesx, Inc. (US) | 2011-03-09 | — | — | EP | claimed |
| EP-2285419-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | Neurogesx, Inc. (US) | 2011-02-23 | — | — | EP | claimed |
| WO-2009143297-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| WO-2009143295-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| WO-2009143299-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| US-20260102294-A1 | ABSORBENT ARTICLE COMPRISING A FRAGRANCE AND AN ODOR CONTROL COMPOSITION | PROCTER & GAMBLE (US) | 2026-04-16 | — | — | US | disclosed |
| EP-0486315-A2 | Process for preparing neotrehalose and its uses | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1992-05-20 | — | — | EP | disclosed |
| EP-0480640-A1 | Lactoneotrehalose, and its preparation and uses | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | PTGS1, HPGD, PYGL | LMNA 3544/4885L3MBTL1 1512/4885TDP1 1999/4885 |
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | LMNA 2401/4885L3MBTL1 3401/4885TDP1 1655/4885 |
| US-20110263545-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | PTGS1, HPGD, PYGL | LMNA 3544/4885L3MBTL1 1512/4885TDP1 1999/4885 |
| US-20260102294-A1 | ABSORBENT ARTICLE COMPRISING A FRAGRANCE AND AN ODOR CONTROL COMPOSITION | CUTA, SHBG, DSG1 | LMNA 2880/4885L3MBTL1 4442/4885TDP1 3090/4885 |
| US-20160264605-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | PTGS1, HPGD, PYGL | LMNA 4170/4885L3MBTL1 1822/4885TDP1 2279/4885 |
| US-20110212926-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | PTGS1, HPGD, PYGL | LMNA 4170/4885L3MBTL1 1822/4885TDP1 2279/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | LMNA 2401/4885L3MBTL1 3401/4885TDP1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.